Radcliffe Capital Management’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Radcliffe Capital Management’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$2.62K	–	476
2023 Q2	$2.62K	Hold	50,000	–	–	﹤0.01%	548
2023 Q1	$4.93K	Hold	50,000	–	–	﹤0.01%	616
2022 Q4	$515K	Hold	50,000	–	–	0.02%	779
2022 Q3	$503K	Hold	50,000	–	–	0.01%	1069
2022 Q2	$500K	Hold	50,000	–	–	0.01%	1123
2022 Q1	$500K	Hold	50,000	–	–	0.01%	1124
2021 Q4	$496K	Hold	50,000	–	–	0.01%	973
2021 Q3	$495K	Buy	+50,000	New	+$20.5K	0.01%	829

Other funds holding ESLAW

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Radcliffe Capital Management's ESLAW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2023, closing a stake of 50,000 shares — an estimated $2.62K sold.

Radcliffe Capital Management first reported a position in ESLAW in Q3 2021 and held it in 8 quarters. The position peaked at $515K in Q4 2022. 11 funds tracked by Wall St. Rank hold ESLAW as of Q3 2023.

Radcliffe Capital Management reported no remaining Estrella Immunopharma Warrant position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 50,000 Estrella Immunopharma Warrant shares in Q3 2023, an estimated $2.62K.
Radcliffe Capital Management first reported a position in Estrella Immunopharma Warrant in Q3 2021 and held it in 8 quarters.
Radcliffe Capital Management's Estrella Immunopharma Warrant position peaked at $515K in Q4 2022.
11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.